Obsidian Therapeutics (NASDAQ:OBX) Stock Short Interest Rises 210.7%

Obsidian Therapeutics (NASDAQ:OBX) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 253,084 shares, a growth of 210.7% from the August 31st total of 81,457 shares. Based on an average trading volume of 314,739 shares, the short-interest ratio is currently 0.8 days. Approximately 0.4% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. TD Cowen initiated coverage on shares of Obsidian Therapeutics in a research note on Thursday, August 6th. They set a “buy” rating on the stock. Wall Street Zen upgraded shares of Obsidian Therapeutics to a “sell” rating in a research report on Saturday, September 19th. Leerink Partners assumed coverage on Obsidian Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $32.00 price objective on the stock. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research report on Thursday, August 6th. Finally, Lifesci Capital began coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $43.00 target price for the company. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Obsidian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Obsidian Therapeutics Stock Down 4.1%

Shares of NASDAQ:OBX traded down $0.55 on Friday, reaching $12.86. 454,476 shares of the company were exchanged, compared to its average volume of 641,407. Obsidian Therapeutics has a 1-year low of $12.16 and a 1-year high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.